Molecular Testing and First-Line Treatment Selection in ALK-Positive NSCLC
Panelists discuss the importance of molecular testing in NSCLC, particularly for ALK rearrangements, and explore how recent advancements and emerging technologies are shaping first-line treatment selection for ALK-positive patients.
- Please provide an overview of the importance of molecular testing in NSCLC, particularly focusing on ALK rearrangements.
- How has the landscape of ALK testing evolved in recent years, and are there any emerging technologies or approaches that might impact your ability to identify ALK-positive patients?
- What is your approach to first-line treatment selection for ALK-positive disease in patients with NSCLC?
Related Content:
